Identity, collaboration and radical innovation: The role of dual organisation identification by O'Malley, Lisa et al.
  1 
 
Identity, Collaboration and Radical Innovation: 
 The Role of Dual Organisation Identification 
 
 
By 
Lisa O’Malley*  
Department of Management and Marketing  
Kemmy Business School 
University of Limerick  
E-mail: lisa.omalley@ul.ie 
 
Michele O’Dwyer  
Department of Management and Marketing  
Kemmy Business School 
University of Limerick  
E-mail: michele.odwyer@ul.ie 
 
Regina C. McNally  
Department of Management and Marketing  
Kemmy Business School 
University of Limerick  
E-mail: regina.mcnally@ul.ie 
 
Stephen Murphy 
Department of Management and Marketing  
Kemmy Business School 
University of Limerick  
E-mail: stephen.murphy@ul.ie 
 
 
*Corresponding Author 
 
March 2014 
  2 
 
Identity, Collaboration and Radical Innovation: 
 The Role of Dual Organization Identification 
 
 
Abstract 
 
This paper explores the nature of the relationship between identity and the 
radical innovation process in the case of the Solid State Pharmaceutical 
Cluster (SSPC). Antecedents and consequences of identification with the 
SSPC and the transitioning of identify from an organizational orientation to a 
dual organisation identity are discussed. We demonstrate that organizational 
identity can represent a substantial barrier to collaborating for radical 
innovation, and explicate how identity shifts can smooth the transition from 
competitor to collaborator. This study illustrates that opportunities were 
created through leveraging affinity to provide an environment conducive to 
radical innovation where members could interact, explore and collaborate.  
 
 
 
Keywords: Identity, Collaboration, Innovation Network, Dual Organization 
Identification 
 
Research Highlights: 
 
1. Identification with a parent organisation can represent a substantial 
barrier to collaboration for subsidiaries within regional networks. 
2. Working together on a specific common problem is fundamental to 
learning how to collaborate.  
3. Dual organizational identification allows individuals to contribute to 
multiple agendas without any apparent conflict of interest.  
4. Collaboration should not be overprescribed at the outset as this 
limits the possibilities for RI. 
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Identity, Collaboration and Radical Innovation: 
 The Role of Dual Organization Identification 
 
 
Introduction 
A radical innovation (RI) requires substantially different technology and 
marketing skills compared with existing offerings within an industry (Chandy 
and Tellis 1998). As is evident in this concept, the term ‘radical innovation’ 
typically relates to new products, although it also applies to new services and 
new processes. A key construct in facilitating efficient and effective innovation 
processes is that of innovation networks (Powell, Koput and Smith-Doerr 
1996). Localised networks have sprung up around the world – e.g. Silicon 
Valley, Ireland, and Taiwan (Bresnahan, Gambendella and Saxenian, 2001) – 
and can include R&D organisations, universities, and research laboratories 
(Lee, Lee, and Pennings, 2001). Such localised networks are regarded as an 
important antecedent to radical innovation (Gordon and McCann, 2000), and 
have been encouraged and supported by governments in many countries. 
Central to the development of regional networks is the belief that geographical 
proximity and cultural sensitivity result in more effective knowledge transfer 
than that experienced between multi-national companies (MNCs) and their 
overseas subsidiaries (Birkinshaw and Hood, 1998). This may be particularly 
the case for collaborations involving established firms with clearly developed 
identities and affiliations. However, not all inter-organizational collaborations 
result in innovation (Faems, Van Looy and Debackere, 2005), with many 
failing to generate any collective action at all (Lawrence, Hardy and Phillips, 
2002). Thus, the question that drives our research is why do some multi-
organisation collaborations work well while many fail?  
 
Radical innovations are generally juxtaposed with incremental innovations, 
which are modifications to existing products (Chandy and Tellis 1998). This 
juxtaposition of terms suggests that ‘innovativeness’ varies from minimal 
change to dramatic change. Furthermore, innovativeness is multi-
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dimensional: newness can be examined from the perspective of the customer 
and from the perspective of the firm in terms of technology and/or the market 
(McNally, Cavusgil, and Calantone 2010). Newness is one of the many 
planned and unplanned, permanent and transient, attributes and features that 
shape stakeholder perceptions of the organisation (Markwick and Fill, 1995; 
Gioia et al. 2000), thereby forming the basis of its identity. Identity is “the 
articulation of what the organisation is, what it does and how it does it, and is 
linked to the way an organisation goes about its business and the strategies it 
adopts” (Markwick and Fill, 1995: 397). An articulate and authentic identity 
increases organizational visibility while providing competitive advantage and 
helping to communicate corporate strategy (van Riel and Balmer, 1997). 
Thus, identity is critical in organizational sustainability (Gioia et al. 2000).  
We examine a multi-organisation collaboration in the Irish pharmaceutical 
industry that is regarded as highly successful based both on members views 
and funding achieved. Our research finds that members of the individual 
organisations transitioned from identification solely with their organisation to 
dual organisation identification, where members of the inter-organizational 
collaboration simultaneously developed a sense of identification with two 
different organizational entities (Vora and Kostova 2007). Within the Irish 
Pharmaceutical industry, these two separate identities (own organisation  and 
SSPC) work in a symbiotic manner, supporting and improving each other 
through two-way, symmetrical, and simultaneous feedback that allows the 
collaboration to operate effectively. As such, we demonstrate how 
identification with one’s parent organisation can represent a substantial barrier 
to collaboration within regional networks. However, collaboration is legitimised 
and embedded within on-going RI activities where members exhibit dual 
organizational identification.  
This paper is structured as follows. First, we explore literature on radical 
innovation, identity, organizational identification and dual organisation 
identification. Next, we characterize the Irish pharmaceutical industry as the 
context in which a successful collaboration across multiple firms and 
universities took place, and explain the research method employed in this 
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study. The findings are discussed in terms of the barriers to collaboration, the 
transitioning of identity from a single organizational orientation to a dual 
organizational identity, and the consequences of this for the studied 
collaboration. Finally, we extrapolate insights from these findings and provide 
directions for further research into understanding the dynamics of identity and 
collaboration in the context of radical innovation as well as highlighting 
recommendations for managers and policy makers on supporting regional 
networks.  
 
Radical Innovation  
Antecedents of, and processes supporting, incremental innovation have been 
well documented and receive considerable empirical support, while the 
antecedents and processes related to radical innovation (RI) are not well 
documented (McDermott and O’Connor 2002). This may be due to the higher 
degree of informality, intense communication and cooperation among actors, 
a lack of decision-making rules, and the emphasis on creativity and risk-taking 
required for radical innovation relative to incremental innovation (Gatignon et 
al., 2002; Song and Swink, 2002). In terms of the process, radical innovation 
develops through phases of exploration, design and applications, and 
dissemination (Lundgren, 1995; Möller, 2010; Anderson and Tushman, 1990), 
and produces fundamental changes in the activities of an organisation and 
large departures from existing practices (Ettlie and Subramaniam, 2004).  
Because few firms have the necessary resources for RI internally, 
collaboration between firms has been viewed as an important driver of 
innovation (Chesbrough 2003; Story, O’Malley and Hart, 2011), so much so, 
that it is promoted and encouraged by governments worldwide (Etzkowitz and 
Leydesdorff 2000; Mowery and Rosenberg 1993).  
Adding to previous conceptualisations of RI, we argue that some collaborative 
efforts should themselves be considered a radical innovation because they 
represent a radical departure from how firms historically interact with each 
other. In this paper, we consider the case of the Solid State Pharmaceutical 
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Cluster (SSPC) in Ireland to highlight (i) the barriers to collaboration as 
perceived by its original members, (ii) the identity change which facilitated 
success, and (iii) the consequences of collaboration including significant 
changes to these firms’ business models. Moreover, while the collaboration is 
itself a radical innovation, importantly, it has paved the way for more material 
innovations in product and process.  
 
Identity 
“To understand identification, one must first understand identity” (Ashforth, 
Harrison, and Corley 2008, p. 327). Identity has been examined from the 
perspectives of social identity theory and identity theory. Social identity theory, 
developed by Tajfel (1978) and Tajfel and Turner (1986), separates social 
identities from personal identities. Whereas personal identities are individuals’ 
idiosyncratic bundle of attributes, such as traits, abilities, and interests, social 
identities relate to group memberships, are shared by group members, and 
distinguish ‘ingroup’ members from ‘outgroup’ members (Tajfel 1978, Tajfel 
and Turner 1986). Identity theory relates to the meanings individuals 
associate with roles, such as occupations, careers, and relational networks 
(Stryker and Burke 2000). Roles are embedded in valued relational networks; 
the likelihood of roles being ‘enacted’ (i.e. activated and performed) increases 
with the value the individual places on the relationships (Burke and Reitzes 
1991). Within organisations the core of identity consists of cognitions related 
to group membership (Tajfel 1978), which include values, goals, beliefs, 
stereotypic traits, and knowledge, skills, and abilities (Ashforth, Harrison, and 
Corley 2008). We argue that while the core aspects of identity are always 
exhibited, the broader content operates more independently and individuals 
vary in the extent to which they embody organizational identities.  
 
Organizational Identification 
Organizational identification occurs when an individual’s beliefs about his or 
her organisation are recognised or adopted as their own. Ashforth and Mael 
(1989) suggest that identification relates to aggregates of people, where 
aggregation occurs at various levels of groupings, including organisations, 
business units, departments, work groups or teams (Ashforth, Harrison, and 
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Corley 2008). ‘Lower-order’ identities, or smaller and more proximal groupings 
such as those an individual works with most frequently and intensely, 
generally evoke stronger identifications. Organizational identities generate 
strong identification when the organizational identity is of very high status, it is 
under perpetual threat, it is unique, the identity is strongly and widely held 
across subunits, if decision-making is highly centralized, and when individuals 
are owners, senior executives, or boundary spanners (Ashforth, Harrison, and 
Corley 2008). 
 
Organizational identification is an iterative, developmental process involving 
interaction between individuals and organisations (Ashforth, Harrison, and 
Corley 2008, Pratt 1998). From the perspective of individuals, the 
identification process involves enactment, sensemaking, and identity narrative 
construction (Ashforth, Harrison, and Corley 2008). Enactment occurs when 
individuals ‘try on’ an identity (i.e. individuals attempt to behave as they 
expect someone with that identity to behave). The next step of sensemaking 
involves observing responses to their behaviour and interpreting the meaning 
of such responses. In the final step, they update their personal story of who 
they are and who they are likely to become. 
 
Within organisations, individual identification is supported and managed 
through a process involving sensebreaking and sensegiving (Ashforth, 
Harrison, and Corley 2008). Sensebreaking ‘involves a fundamental 
questioning of who one is when one’s sense of self is challenged … [creating] 
a meaning void that must be filled’ (Pratt 2000, p. 464). Thus, sensebreaking 
accentuates knowledge gaps to motivate further identity exploration, creating 
tension and resulting in a search for meaning. This tension and search for 
meaning enhances the opportunity for sensegiving, which refers to attempts 
to guide the ‘meaning construction of others toward a preferred redefinition of 
organisation reality’ (Gioia and Chittipeddi 1991, p. 42).  
 
Pratt (1998) suggests there are two alternative processes of identification: 
emulation and affinity. The iterative, back-and-forth process explained above 
captures the ‘identification through emulation’ process (Ashforth, Harrison, 
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and Corley 2008), where identification occurs when individuals incorporate 
organisation beliefs and values into their own identities (Pratt 1998). In 
identification through affinity, “like meets like” (Pratt 1998, p. 174); here, 
individuals use their own identity to assess if an organisation has values and 
beliefs similar to their own.  
 
Dual Organizational Identification 
Dual organizational identification (DOI) is an individual’s sense of identification 
with two organizational entities (Vora and Kostova 2007). Multiple identities 
can be salient simultaneously when identities overlap, are relevant to a 
specific context, are cognitively linked to each other, and when individuals can 
tolerate such simultaneous identifications (Ashforth and Johnson 2001). 
Research on multiple identifications is scant (Vora and Kostova 2007), and 
examines the multiple identifications separately, without considering how they 
might work together (Gregersen and Black 1992). However, Vora and 
Kostova (2007) develop a conceptual framework regarding how subsidiary 
managers in multinational enterprises (MNEs) simultaneously manage their 
identifications with both the subsidiary and the enterprise.  
 
DOI is complex, consisting of two separate and independent characteristics: 
relative magnitude (the relative strength of the sense of identification with 
each of the two entities) and form (the perceived configuration of the two 
identifications in terms of overlap) (Vora and Kostova 2007). Magnitude is not 
driven by proximity; rather, it is driven by the abilities of each entity to fulfil the 
individual’s self-enhancement and uncertainty reduction needs. With this 
definition of magnitude, it is possible for those in the local subsidiary to 
identify more strongly with the MNE than with the local subsidiary.  
 
In this research, we examine how the identifications of managers in a multi-
organisation collaboration in the Irish pharmaceutical industry evolved from 
identification solely with their MNC to dual organisation identification. In 
particular, we explore how ‘identification through affinity’ enabled changes in 
behaviour that supported RI.  
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Ireland, Industrial Policy, and the Pharmaceutical Industry 
The context of this collaboration involving five Irish universities and nine 
pharmaceutical companies (entitled the Solid State Pharmaceutical Cluster) is 
particularly interesting because the pharmaceutical industry in Ireland is highly 
regulated and insular (Van Egeraat, 2006; Hannon et al., 2011), with firms 
closely guarding intellectual property (Henderson, Orsenigo and Pisano, 
1999). These firms have historically maintained their distance and have no 
history of collaborating with academia (Van Egeraat, 2006; Hannon et al., 
2011), or with each other.  
Historically the Industrial Development Authority (IDA) promoted Ireland as a 
low-cost manufacturing base. This strategy attracted eight of the top ten 
leading international pharmaceutical companies to establish Irish subsidiaries. 
The highly educated, English speaking workforce and attractive corporate tax 
regime further enhanced Ireland’s competitive advantage. However, by the 
early 1990s the Irish economy began to experience such dramatic growth that 
the Irish pharmaceutical subsidiaries became vulnerable to competition from 
subsidiaries in lower cost economies across the world, a situation mirrored in 
other Irish manufacturing-based industries. In order to overcome this 
challenge, the Irish Government through the IDA attempted to shift the 
economy away from reliance on manufacturing and towards the creation of 
discovery laboratories. However, Ireland lacked the necessary infrastructure 
for excellence in science and technology, and collaboration with academia 
was very limited (ICCSTI, 1999 cited in van Egeraat, 2006). Recognising the 
need for collaboration between firms and supported by academia, government 
policy through Science Foundation Ireland (SFI) set out to establish a number 
of centres of excellence in order to advance basic research (Orsenigo, 
Pammolli and Riccaboni, 2001), and create opportunities for innovation 
through “focused attention to common problems” (Department of Enterprise, 
Trade and Employment, 2008, p. 13). Less than a decade ago, collaboration 
was not on these firms’ agendas, and government agencies were acutely 
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aware of the barriers to fostering collaboration. This paper explores how these 
barriers were successfully overcome.  
Central to this paper is a shift in identity by members of the firms involved in 
this collaboration from perceiving themselves primarily as multinational 
subsidiaries that were physically located in Ireland, to identifying more with 
local pharmaceutical firms and with the Irish agenda through the idea of 
‘Ireland Inc.’ This shift in identity was greatly facilitated by the nature of global 
competition within multinational subsidiaries as well as specific changes to 
Ireland’s competitive position within this space. By adopting the rhetoric 
surrounding the challenging times facing Ireland, key actors ensured that the 
pharmaceutical industry, and the SSPC in particular, were at the heart of any 
solution to Ireland becoming an international pharmaceutical hub. Although a 
localised case study, we identify important implications for the creation and 
development of innovation networks in different industries across different 
global locations. In particular, we employ the construct of dual organizational 
identification via the affinity process to explain the transition from identification 
solely with members’ home organisation to simultaneous and strong 
identification with both the home organisation and to the new inter-
organisation collaboration, which enabled the collaboration to sustain itself. 
 
RESEARCH METHOD  
In order to understand the processes through which collaborative activities 
developed within this network, we interviewed the key individuals who initiated 
and developed the SSPC because it was “their perception, interpretation and 
actions” (Makkonen, Aarikka-Stenroos, and Olkkonen, 2012: 291) that created 
[and continues to maintain] this network. Informants were drawn from the five 
universities and nine firms involved in the initiation of the innovation 
collaboration. In total, 18 participants involved in the formation and early 
stages of the SSPC were available for interview. Initial interviews were 
conducted over a three month period in early 2012 and were supplemented 
by further interviews in January 2013. Interviews lasted between 50 and 90 
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minutes. Please refer to Table I for a list of participants (Informant names 
have been changed to protect their anonymity). Because our focus is on the 
barriers to collaboration and how these were overcome, in this paper we rely 
on insights and experiences of the key actors who initiated the SSPC. 
--------------------------------------------- 
INSERT TABLE I ABOUT HERE 
 
Adopting Wengraf’s (2001) structured approach to narrative interviewing, we 
invited key actors to share their understanding of how the network was 
conceived and how collaboration emerged. In so doing we acknowledge that 
informants construct and communicate their experiences through the stories 
they tell (Bruner 1991), and that these stories provide legitimacy and 
accountability for their actions (Czarniawska, 1997). Thus, through narrative 
interviews we accessed “the same kind of data that organizational members 
use to plan, enact, interpret, and evaluate their own actions and those of 
others” (Pentland, 1999: 717). As a result, their understanding of the barriers 
to, and consequences of this collaboration, emerged organically in the stories 
they told. 
Each interview began with a single question intended to induce narrative 
(SQUIN), in our case “tell me the story of the SSPC as you see it.” In this way, 
informants offered a “purposeful account” (Jovchelovitch and Bauer, 2000) of 
how and why the SSPC was formed and the centrality of the participants’ 
roles. Each story (or micro narratives, Boje, 2001) was related orally, from 
memory and, in line with the biographical narrative interpretive method 
(BNIM), started in different places and times and (occasionally) fore-grounded 
different events (Czarniaska, 1997). Informants were in control of their own 
story (Wengraf, 2001). As interviewers, we focused on listening actively and 
on taking notes. Informants responded very differently to this opening 
question with several talking for 20 minutes or more and others struggling to 
speak for 2 minutes. The next phase of the interview followed in a similar 
manner but this time we introduced topic questions aimed at inducing 
  12
narrative (TQUINs). These questions became more specific, i.e. asking for 
more detail about topics raised by the participant during the first phase of the 
interview. The third phase of the interview allowed us to ask questions based 
on our preliminary analysis of the first two phases, as well as theoretical and 
practical questions arising from our emerging understanding of the 
collaboration and from other interviews.  
Each interview was transcribed and appended to notes taken at the time of 
the interview. The first reading of interview accounts was intended to 
appreciate the micro narratives (i.e., the story within the story) (Boje, 2001), 
recognise plots and protagonists as identified by informants, and identify key 
individuals to target for further interviews. Informed by the wider literature on 
innovation networks, knowledge sharing and collaboration, we undertook a 
thematic analysis within, and across, interview transcripts. However, as we 
read and re-read the transcripts we began to appreciate that language, 
metaphor and identity impacted on the creation of this network, and we 
actively sought out theoretical frames that further informed our analysis and 
supported our sense-making processes. We interrogated and supplemented 
our interpretations through reviewing published government reports, the 
SSPC website and related materials. We shared our analysis of the data with 
key actors to ensure they were not being misrepresented. 
 
Findings  
Overcoming Barriers to Collaboration:  
Historically, the atmosphere between multinational subsidiaries was distant 
and fearful, an outcome of the degree to which pharmaceutical companies 
worldwide protect their intellectual property (Henderson, Orsenigo and 
Pisano, 1999). As a result, subsidiary firms maintained distance from other 
pharmaceutical subsidiaries within the same geographical region.   
I would say that ten years ago you were afraid to be talking to 
someone from another competitor company. I suppose there was 
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that level of fear. I don’t know where that originated, [but] there was 
real fear.  [Peter, Pharmaceutical Company 2] 
The parent company decided which of its subsidiaries across the world 
manufactured which product. Philip describes below how this usually worked. 
 Drug discovery would tend to come from head office. They would 
develop it to a certain stage and then they would go into clinical trials. 
And then towards the end of clinical trials they would start to think how 
are they going to manufacture it. And they would typically choose a 
plant, one of their plants around the world. It’s at that stage the Irish 
companies would get involved. And they are competing to be the plant 
that gets the drug. And then they will manufacture it for some years. 
[Philip, University 1] 
The high end activities of drug discovery are primarily located at the parent 
headquarters and manufacturing of the drug takes place around the world. As 
a result, competition is intense between subsidiaries and manufacturing cost 
becomes a significant choice criterion. Thus, the dynamics of internal 
competition between subsidiaries is a critical determinant of which 
subsidiaries survive (Almor and Hirsch, 1995), and is largely driven by the 
track record of those subsidiaries (Birkinshaw and Hood, 1998) and the cost 
climate in which they operate. 
 
One important downside of the growth in the Irish economy around the turn of 
the millennium was that Ireland was becoming less competitive in terms of 
costs, and, as such, their competitive advantage vis a vis sister subsidiaries 
around the world was being eroded:   
We knew that our old manufacturing mandate was not going to serve 
us in the future because of the impact of the Celtic Tiger raising our 
costs significantly. Therefore, we were being challenged on a 
competitive scale by other locations. [William, Pharmaceutical 
Company 1] 
This competition between other MNC subsidiaries became a significant threat 
to the Irish Pharmaceutical industry, and this, perhaps more than anything 
else, initiated the process of sensebreaking (Ashforth, Harrison and Corley 
2008) with Irish firms increasingly regarding their sister subsidiaries as their 
competitors.   
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As you may know, the pharma sector is under threat from India and 
China because they can produce materials much cheaper. [Donald, 
University 1] 
 
In response to this acknowledged threat, industry participants created a 
special interest group, which was central to breaking down the perceived 
barriers between firms. 
Having a group like IBEC1 PharmaChem Ireland, that’s got people to 
get to know each other a bit better and relax a bit to share our 
challenges. In parallel the world was changing and our challenges were 
becoming more and more similar. Losing manufacturing was a problem 
that we all had.  Then we were able to rally around this problem of how 
do we stop hemorrhaging manufacturing out of Ireland? [Peter, 
Pharmaceutical Company 2] 
 
The threat to the pharmaceutical sector was perceived as very real – with the 
various firms experiencing the same challenge of being less competitive than 
their sister subsidiaries in other locations. This was problematic as a number 
of patents were due to expire for blockbuster drugs manufactured in Ireland. 
Therefore, in order to maintain exports and jobs, these companies needed to 
ensure they could successfully compete to manufacture new drugs. Although 
Irish firms were aware that they were also experiencing similar problems vis a 
vis their parent organisations and sister subsidiaries, they continued to identify 
with their parent organisations and maintained their distance from other Irish 
firms. The shift from ‘real fear’ of being seen talking to other firms seems to 
have been overcome by the obligation to save jobs in each of their 
organisations.  
 
For some of the companies, they view [collaboration] as much of a 
strategic benefit to Ireland as it was to their own individual 
companies…. I think the nature of the companies in Ireland [is that] for 
them, their competitors may be sister sites in other countries… [Kevin, 
University 3]. 
 
Thus, because the challenges faced by individual firms became more similar, 
Irish firms began to identify more with each other and there was a perceptible 
                                                          
1
 Pharmachem Ireland is a subsidiary of the Irish Business Employers Confederation (IBEC) that 
focuses on the pharmaceutical and chemical industries in Ireland. 
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shift in identity from ‘we’ [individual firm] to ‘we’ denoting pharmaceutical 
companies in Ireland. This shift occurred because of the increasing cost base 
challenging all firms based in Ireland (we), along with increased competition 
from sister subsidiaries, particularly China and India (them). The shift to ‘we’ 
denoting pharma Ireland was also facilitated through identification with, and 
participation in the local Business confederation (IBEC) as a specific industry 
grouping. Following several meetings and discussions, this group produced a 
Strategic Plan for the industry in Ireland. In this they linked the fate of the Irish 
pharmaceutical industry to the fate of the Irish economy, delineating that a 
sector contributing 56% of Irish Exports, accounting for more than €40 billion 
annually, could not be allowed to fail: 
Ireland depends heavily on the pharmaceutical sector which generated 
over 50% of Irish exports, worth some €44 billion, in 2008. Responding 
to the challenges facing the sector must be a national priority. In order to 
remain the great success story that Ireland has become, industry, 
government and other related stakeholders need to meet these 
challenges head on. Companies need to respond by linking research 
directly to manufacturing, via process and product development. 
(Innovation and Excellence PharmaChemical Ireland Strategic Plan).  
 
When SFI announced a call for applications for the development of Strategic 
Research Clusters, Philip invited industry to come on board.  
So we approached the industry then and we just profiled the kind of 
capacities which we had. They were very interested in the 
presentation that we made. There was some big names there who 
were opinion leaders…. they were all quite supportive of the whole 
idea. They said this expertise is something that we definitely lack in 
Ireland. [Philip, University 1]. 
 
This response marked a further transition in the identity of the individual 
pharmaceutical companies who were beginning to align more with the 
challenges facing other Irish pharmaceutical companies, than they were with 
their parent organisation. This was essential in overcoming their historically 
competitive stance – a significant barrier to collaboration. While Philip 
anticipated that only two or three firms would get involved in the initial 
programme, articulation of the capacities and expertise held by the academics 
proved far more attractive than expected. 
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[Philip] was actually surprised with how receptive we were to his 
proposal… He went around the companies and I think of all the 
companies only one turned him down and he ended up with 9 
companies that would be prepared to work together with the institutions. 
[Peter, Pharmaceutical Company 2] 
 
Collaborative Consequences: After the Introduction of the SSPC 
The SSPC was established in 2007 as one of three Strategic Research 
Clusters, and secured funding of €6.97 million from SFI. Its focus was to 
support knowledge networks to create distinctive competences that would 
ensure that Ireland remained competitive in the global pharmaceutical 
industry (Hannon et al., 2011). The SSPC was formed ostensibly to 
conduct research in the area of crystallization of pharmaceutical solids and 
has since developed and utilized important RI competences. Since its 
inception, members of the SSPC have engaged in a number of successful 
research collaborations, have developed the Best Practice Crystallisation 
Website and initiated collaborations outside of the crystallisation space. 
Indeed, such has been their success that within 5 years additional funding 
of €40 million had been secured in order to establish The Synthesis and 
Solid State Pharmaceutical Centre – involving 17 pharmaceutical 
companies working with 90 researchers across 8 academic institutions. 
Before the SSPC was formalised, Irish firms (like their global counterparts) 
maintained arm’s length relationships with competitor subsidiaries 
(Henderson, Orsenigo and Pisano, 1999). 
 
In September 2008 the academic partners rolled out training modules for 
collaborating partners, in various locations, on topics relating to 
crystallisation to build a common identity. High level training was provided 
which focused on demonstrating the underlying research behind the 
processes in which they were actively involved. This served to overcome 
participants’ reticence to share information, embedded a culture of 
collaboration and established opportunities to develop and demonstrate 
competences for further radical innovation activity. In addition the SSPC 
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embarked upon an ambitious venture to create a ‘best practice 
crystallization port’. 
We decided to create a best practice crystallization port… So we 
looked at the manufacturing process of an active ingredient and we 
divided it into logical blocks and see if we can put teams together 
that will study the state of the art in terms of literature and what is 
happening in companies and write a best practice approach for 
crystallization of the pharmaceutical compound. So we said let’s put 
some academics, students and industry people from different 
companies into 8 groups and put them working together. We ended 
up with about 64 people working on this and I think the fact that we 
did this and we had the training done kind of gelled the cluster early 
on. It broke down a lot of barriers because all of these people were 
openly sharing information about how to do things. [Tom, University 
1]. 
Within two years SSPC developed the Best Practice in Crystallization website 
(BPX) that launched on the 6th of November 2009.  The formation of BPX.ie 
resulted from the combined efforts of academic and industrial members of the 
SSPC, working together to define the current state of the art in 
pharmaceutical crystallization. As such the BPX website is recognized within 
the network as a testament to the success achieved through collaboration. A 
major part of the process was capturing tacit knowledge and sharing it 
through this purpose built website, which had a profound impact on the 
learning community and its identity. As a result, it exceeded the expectations 
of those who initiated the collaboration: 
Companies came together and had a look at it and found that they 
were actually getting more value than they expected. They thought that 
it would just be the getting to know you bit at the beginning. But 
companies actually started to really buy into it. It was the first time they 
thought it was a relationship and they were learning. They found that 
they were learning as much from their peers as they were from the 
academics. [Donald, University 1]. 
Initially framed as Ireland Inc. against the ‘sister companies’ in the global 
marketplace, one participant identifies how this has in some sense come full 
circle with the parent companies now benefiting too: 
I was in New York two weeks ago and I did a presentation to all of 
the R&D, about 120 people from [Pharmaceutical Company 2] and 
all of the manufacturing people, and basically I put up the website 
and very simply said to them if you’re planning on doing 
crystallization next Monday morning - don’t - Log onto this website 
first. I sent a very clear message to all of the people there and I’m 
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sure Tom had a lot more people looking for entry and I’m sure he 
must have about 200 people from [Pharmaceutical Company 2] 
looking for entry. Their reaction is “Oh my God, you’re sharing stuff 
with [other Pharmaceutical]?”, followed by “Can we get access to 
it?”… That’s what the cluster is about, its taking that common 
knowledge and putting it into one place. It’s very powerful.  [Peter, 
Pharmaceutical Company 2] 
Peter’s narrative provides some relevant perspective and context on the level 
of radical innovation achievement that the SSPC has attained. Here, we see 
how the best practice website represents an on-going resource that is also 
valuable to parent organisations. This demonstrates that identification with 
other Irish firms did not undermine subsidiaries’ identification with their parent 
firms. Rather, through dual organizational identification (Vora and Kostova, 
2007), the benefits of collaboration became available to all. While Peter’s 
colleagues at Pharmaceutical Company 2 were initially shocked at the fact 
that this information was being shared with others (competitors), their next 
reaction was to look for access. Therefore, value is ultimately created for the 
Irish firm as they gain a specific area of expertise, which aids them in 
competing against sister firms within their own corporate structure.  
When they have a success like the one I described they will go and 
communicate their successes to head office, and their kudos is 
growing…. The bigger the company the more they tend to 
communicate with head office. They just want them to know what’s 
going on. Sometimes there is a kind of perverse delight in saying 
corporate couldn’t solve this problem but we did. [Philip, University 1] 
Thus, Irish firms grew in confidence and were able to clearly demonstrate 
valuable innovation activity and outcomes to their parent organisations. When 
seeking approval from host organizations for ongoing collaborative activities, 
they spoke in terms of return on investment and the potential to add value, 
and this was fundamentally to ensuring senior management commitment to 
their participation in the SSPC. Moreover, as the collaboration evolved, 
through a process of engagement and interaction the ‘program for action’ 
evolved and became more relevant not only to the problems they currently 
faced, but also to problems they anticipated in the future:  
The whole thing emerged. The whole thing has changed in the five 
years. We had lots of discussions around that time and you wouldn’t 
have been able to predict 5 years ago where we are now. Because we 
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started off with a programme for SFI …. [but] at the mid-term review 
three years later, it was all completely different.  The interaction with 
the different colleagues, particularly industry colleagues, was hugely 
influential. They kind of know what’s coming down the line, you know. 
They know the technology that they are not using today but that they 
expect to be using in two years’ time. And that’s what they want from 
the cluster. [Philip, University 1] 
 
DISCUSSION  
The SSPC is presented here as a successful innovative collaboration 
among ostensibly competing firms to further their ability to succeed in a 
highly competitive global marketplace. In terms of understanding how this 
innovation collaboration works so effectively, we demonstrate the key role 
of affinity in transitioning members from organizational identification to dual 
organizational identification. The common ground for the different 
stakeholders involved in the SSPC (i.e., educational institutions, 
pharmaceutical companies) was a desire to see Ireland develop as an 
international pharmaceutical hub. Achieving this did not require any 
alteration of individual values or beliefs (i.e., the organizational identity 
could remain the same), but based on recognition of shared core common 
values and beliefs, affinity with a new identity was not only possible, but 
also supported a rapid shift to dual organisation identification.  
The members to whom we spoke articulated the importance of the SSPC 
and their identification with it. This contrasted significantly from their original 
identity as subsidiaries of a multinational parent organisation competing 
with other pharmaceutical firms in Ireland. The shift in identification allowed 
them first to view sister subsidiaries as their competitors for manufacturing 
business, and second, to view other Irish firms as potential collaborators. It 
was this that allowed them to benefit from the geographical proximity and 
cultural sensitivity that is central to successful regional innovation activities 
(Birkinshaw and Hood, 1998). This transition enabled members to engage 
in the kinds of effective collaboration essential to the discovery stage of RI 
(see Story, O’Malley and Hart, 2011).  
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Having recognised the value of securing the future of the Irish Pharmaceutical 
Industry by securing a strategic research cluster, the original members of the 
SSPC established a basis for collective engagement by successfully 
defending the SSPC proposal to the expert panel.  
I think a lot of the way that the companies here are looking at this is 
that they have to fight their corner in some respects for the Irish 
facility against their sister companies in other countries. So if they 
can show capability in Ireland, that does all of the companies that 
are based here good. It means that there is a strength developed 
within the country. [Donald, University 1] 
In explaining the new mindset, Donald illustrates the gravity of the 
challenges faced by the Irish pharmaceutical sector. By individually aligning 
with the “Irish facility” of the company, there seems to be a perceptible shift 
toward country over company, as evidenced by other narratives. 
Obviously people’s first responsibility is to their companies but there 
is a kind of commitment to Ireland Inc., as they say, you know. 
People are proud of the success of the industry in this country and 
people are generally very happy to see the success of other 
companies here. On a local level, the cooperation is much stronger 
than competition… [Geoff, Pharmaceutical Company 3] 
By creating this meaningful Irish subsidiary identity, local management was 
empowered to “take certain actions for the benefit of their country and for 
themselves” (Birkinshaw and Hood, 1998, p. 774). In terms of the latter, 
this shift in identity enabled collaboration that could fundamentally change 
the competitive landscape (Leifer et al., 2000).  
 
The way in which firms are structured in a global economy results in a more 
tangible competition between subsidiaries in other countries, rather than with 
competitors in Ireland. Firms are beginning to recognise the advantages that 
can be gained through pooling resources and expertise and this is reflected in 
a more open attitude towards collaboration and shared identity. Importantly, 
this rationale enabled group members to “construct themselves, the problem, 
and the solution as part of a collaborative framework in which the potential for 
joint action is both significant and beneficial” (Hardy, Lawrence and Grant, 
2005, p. 63).  
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Addressing the problems facing the pharmaceutical industry became an 
Irish problem, involving not only industry participants but also government 
and academia. This served to identify government and academia as 
important stakeholders with significant resources to be called upon.  
Equally, by articulating the SSPC proposal as a collaboration between 
industry and academia, they aligned with government policy to create 
strategic research clusters and with Ireland’s ambition to become a 
‘knowledge economy’. While this highlights the utility of government policy 
to support radical innovation activities through collaboration, it also 
demonstrates that the availability of public funding is a necessary but 
insufficient condition. Localised efforts to identify and overcome barriers to 
collaboration are fundamental to successful regional RI activities.  
Irish firms needed to demonstrate their technical superiority over sister 
subsidiaries and this helped to form the basis of an alternative identity.  The 
desire to be part of something bigger through the articulation of Ireland Inc 
provided the necessary glue. Thus, an emergent identity provided a basis 
by which participants could identify issues as being “relevant to their 
organisation and consequently identifying themselves as interested and 
affected by it” (Hardy, Lawrence and Grant, 2005, p. 64). This created the 
basis of a new collective identity that facilitated the initial collaboration.  
The leaders within the SSPC recognized the importance of affinity to 
collaborative innovation activities and, on this basis; they successfully 
adjusted the use of terminology in relation to the exchange partners they were 
addressing. By focusing on the specific problem of crystallization a new 
identity emerged around SSPC and this inspired synergistic action. Thus, 
focusing on a specific common problem was fundamental to learning how to 
collaborate and to advancing their shared vision of Ireland as having a strong 
international pharmaceutical industry.  
CONCLUSION  
 
Given that collaboration between firms has become increasingly important for 
radical innovation (Story, O’Malley and Hart, 2011), localised innovation 
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networks involving R&D organisations, universities and research laboratories 
(Lee, Lee and Pennings, 2001) have been developed in various countries 
around the world (Bresnahan, Gambendella and Saxenian, 2001). Because 
such networks are localised, firms’ geographical proximity and cultural 
sensitivity are argued to result in better knowledge transfer than is possible 
between MNCs and their overseas subsidiaries (Birkinshaw and Hood, 1996).  
However, the development of localised innovation networks is not always 
unproblematic and without significant barriers. 
This case demonstrates that less than a decade ago, collaboration 
between Irish pharmaceutical firms was considered impossible because of 
the highly competitive atmosphere that existed (Van Egeraat 2006; Hannon 
et al., 2011). This, we argue, resulted from local subsidiaries identifying 
solely with their parent organisations. However, changes in the global 
economy together with dramatic increases in Ireland’s cost-base resulted in 
Irish firms beginning to view their sister subsidiaries in other countries as 
their competitors (competing for opportunities to manufacture new drugs) 
thereby initiating a process of sensebreaking in terms of identification with 
parent firms. Moreover, because this was a challenge faced by all Irish 
subsidiaries vis a vis subsidiaries in other countries, they began to identify 
with other Irish subsidiaries and with the potential loss of pharmaceutical 
employment as an Irish problem. Importantly, involvement in IBEC created 
a platform for engagement and discussion and, ultimately, a readiness for 
collaboration. Thus, when one Irish university proposed establishing a 
formal collaboration between universities and the pharmaceutical industry 
the majority of firms came on board willingly, and began to identify with the 
SSPC. However, they did not eschew one identity (parent MNC) in this 
process; rather what emerged was dual organizational identification (Vora 
and Kostova, 2007). Thus, members of the Irish pharmaceutical industry 
were able to collaborate with each other and to benefit from the 
geographical proximity and cultural sensitivity that is central to successful 
regional innovation activities (Birkinshaw & Hood, 1998). By overcoming 
barriers to communication, members of the SSPC were able to engage in 
the kinds of effective collaboration essential to t
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(see Story, O’Malley and Hart, 2011). However, members did not eschew 
identification with their own organisations. Rather, they were able to share 
insight and knowledge with their parent organisations.  
Collaboration is crucial to the development of radical innovations (Gordon and 
McCann 2000; Story, O’Malley and Hart 2011). Thus, if industry members 
can’t or won’t interact (as was previously the case for members of the Irish 
pharmaceutical industry), then collaboration does not occur. This paper 
demonstrated how firms in this study were able to engage in collaborative RI 
activities through the development of dual organizational identification. This 
allows them to contribute both to their own organizational agenda and to the 
SSPC without any apparent conflict of interest.   
There are important insights for radical innovation theory development that 
can be extrapolated from this study. First, context specific narrative accounts 
provided in this study extend our understanding of the process through which 
fundamental changes in the business model (necessary for RI) are enacted 
(Ettlie and Subramaniam, 2004). Where the collaboration is a radical 
departure from traditional ways of operating, shifts in identity and identification 
may be necessary to overcome barriers to engagement. In the case of the 
SSPC, opportunities were created through leveraging affinity to provide an 
environment conducive to radical innovation where members could interact, 
explore and collaborate.  
 
In considering these findings it should be noted that the research 
methodology adopted for this study was exploratory (as required for the 
theory building necessary for this study) and was limited to the key actors 
involved in establishing the SSPC. Future research should extend the 
qualitative research to include key stakeholders in the SSPC to explore a 
more holistic interpretation of dual organisation identity. In addition we 
propose that a quantitative study, with a wider group of stakeholders from 
within the network, be developed in order to suggest a model to map the 
transitioning from organizational identification to dual organisation identity, this 
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could be replicated with successful innovation networks in other regions for 
comparison.  
 
In terms of managerial implications, it is clear that creating a dual 
organizational identification enabled local firms to engage in collaboration 
within the pharmaceutical industry in Ireland and to also share emerging 
resources with their parent firms. Thus, opportunities must be created to 
ensure that learning can be shared, so that the parent organisation can see a 
benefit from their subsidiary collaborating within the local innovation network. 
It is also clear that the agenda for action must be fluid. It must be capable of 
responding to opportunities as they present themselves (funding bids, 
practical problems etc.), rather than articulating a priori how and when 
interaction will occur. If SSPC had followed a prescribed template from the 
outset, it would be far more limited in its intentions than it currently is, and 
would have celebrated far fewer successes. The creation and co-ownership of 
the website is testament to this, as is the invitation extended to parent and 
sister firms to avail of this resource. Thus, while this collaboration is in itself 
radical – importantly, it has led to further changes in how firms interact and 
identify with each other and with their parent organizations. In doing so, it also 
has enhanced the potential for all to engage in more RI activities thank could 
have been possible prior to the formation of the SSPC. 
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NOTES 
 
1. IBEC is a business networking forum and within this there had been a 
pharmaceutical group in existence since 1994. Strategic issues were 
discussed but no formal collaboration had emerged until after the proposal for 
the SSPC cluster. 
2. The academic contributors are University of Limerick, National University of 
Ireland, Galway, Trinity College Dublin, University College Dublin, and 
University College Cork. The Pharmaceutical Company members are 
Janssen, Schering Plough, GlaxoSmithKline, Merck Sharpe and Dohme, 
Roche, Pfizer, Eli Lilly, Clarochem, Hovione, and Bristol Myers Squibb. 
3. SSPC website is 
http://www2.ul.ie/web/WWW/Faculties/Science_%26_Engineering/Research/
Research_Institutes/MSSI/Research_Themes/SSPC/Governance 
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TABLES 
 
Table 1: Informants 
Informant Organisation Experience Context 
 
1/Philip  
University 1 Industry and Academic   
2/Donald University 1 Industry and Academic   
3  University 1 Industry and Academic   
4  University 2 Industry and Academic   
5/Kevin  University 3 Industry and Academic   
6  University 4 Industry and Academic   
7  University 5 Industry and Academic   
8/William  Pharmaceutical Company 1 Industry and Academic   
9/Peter Pharmaceutical Company 2 Industry and Academic   
10/Geoff  Pharmaceutical Company 3 Industry and Academic   
11  Pharmaceutical Company 4 Industry 
12  Pharmaceutical Company 5 Industry  
13  Pharmaceutical Company 6 Industry and Academic   
14  Pharmaceutical Company 7 Industry and Academic   
15  Pharmaceutical Company 8 Industry  
16  Pharmaceutical Company 9 Industry   
17  Pharmaceutical Company 10 Industry   
18  Pharmaceutical Company 11 Industry and Academic   
 
 
 
 
  
